Assignee
HOPE CITY
US·581 granted patents·322 pending applications·10,748 citations·filing 1981–2025
Top patents by PatentIndex Score
903 records- 0198US9803218B2Recombinant adeno-associated vectors for targeted treatmentHOPE CITY·Filed 2016·Granted Oct 31, 2017·37 cites·46 claims
- 0298US9783825B2Recombinant adeno-associated vectors for targeted treatmentHOPE CITY·Filed 2017·Granted Oct 10, 2017·35 cites·39 claims
- 0398US9777291B2Recombinant adeno-associated vectors for targeted treatmentHOPE CITY·Filed 2017·Granted Oct 3, 2017·35 cites·33 claims
- 0498US5837821AAntibody constructHOPE CITY·Filed 1992·Granted Nov 17, 1998·471 cites·19 claims
- 0597US9890396B2Adeno-associated virus vector variants for high efficiency genome editing and methods thereofHOPE CITY·Filed 2016·Granted Feb 13, 2018·31 cites·85 claims
- 0697US8927514B2Recombinant adeno-associated vectors for targeted treatmentHOPE CITY·Filed 2012·Granted Jan 6, 2015·227 cites·15 claims
- 0797US8691786B2Methods and compositions for the specific inhibition of gene expression by double-stranded RNAHOPE CITY·Filed 2013·Granted Apr 8, 2014·24 cites·61 claims
- 0897US7514537B2Chimeric immunoreceptor useful in treating human gliomasHOPE CITY·Filed 2005·Granted Apr 7, 2009·230 cites·4 claims
- 0997US7446179B2CD19-specific chimeric T cell receptorHOPE CITY·Filed 2001·Granted Nov 4, 2008·453 cites·5 claims
- 1097US7446191B2DNA construct encoding CE7-specific chimeric T cell receptorHOPE CITY·Filed 2008·Granted Nov 4, 2008·450 cites·2 claims
- 1197US7354762B2Method for producing CE7-specific redirected immune cellsHOPE CITY·Filed 2007·Granted Apr 8, 2008·312 cites·1 claims
- 1297US7265209B2CE7-specific chimeric T cell receptorHOPE CITY·Filed 2006·Granted Sep 4, 2007·397 cites·1 claims
- 1397US7070995B2CE7-specific redirected immune cellsHOPE CITY·Filed 2002·Granted Jul 4, 2006·486 cites·4 claims
- 1497US6410319B1CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignanciesHOPE CITY·Filed 1999·Granted Jun 25, 2002·719 cites·22 claims
- 1596US10357571B2Development of masked therapeutic antibodies to limit off-target effectsHOPE CITY·Filed 2015·Granted Jul 23, 2019·18 cites·8 claims
- 1696US9976147B2STAT3 inhibitors and uses thereofHOPE CITY·Filed 2016·Granted May 22, 2018·13 cites·24 claims
- 1796US9839696B2Recombinant adeno-associated vectors for targeted treatmentHOPE CITY·Filed 2017·Granted Dec 12, 2017·11 cites·24 claims
- 1896US9834789B2Recombinant adeno-associated vectors for targeted treatmentHOPE CITY·Filed 2017·Granted Dec 5, 2017·12 cites·14 claims
- 1996US9623120B2Recombinant adeno-associated vectors for targeted treatmentHOPE CITY·Filed 2014·Granted Apr 18, 2017·62 cites·18 claims
- 2096US9574014B2Chimeric antigen receptor compositionsHOPE CITY·Filed 2016·Granted Feb 21, 2017·41 cites·20 claims
- 2196US5981176AMethod of detecting and discriminating between nucleic acid sequencesHOPE CITY·Filed 1992·Granted Nov 9, 1999·511 cites·11 claims
- 2295US9605266B2Cell-specific internalizing RNA aptamers against human CCR5 and uses thereforeHOPE CITY·Filed 2015·Granted Mar 28, 2017·24 cites·12 claims
- 2395US9492222B2Coaptive surgical sealing toolHOPE CITY·Filed 2015·Granted Nov 15, 2016·34 cites·16 claims
- 2494US11690908B2Use of endogenous viral vaccine in chimeric antigen receptor T cell therapyHOPE CITY·Filed 2021·Granted Jul 4, 2023·3 cites·10 claims
- 2594US11591596B2Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereofHOPE CITY·Filed 2020·Granted Feb 28, 2023·3 cites·34 claims
- 2694US11116834B2Use of endogenous viral vaccine in chimeric antigen receptor T cell therapyHOPE CITY·Filed 2017·Granted Sep 14, 2021·10 cites·11 claims
- 2794US10961538B2Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapyHOPE CITY·Filed 2019·Granted Mar 30, 2021·7 cites·15 claims
- 2894US9914909B2Costimulatory chimeric antigen receptor T cells targeting IL13Rα2HOPE CITY·Filed 2016·Granted Mar 13, 2018·21 cites·16 claims
- 2994US9828342B2Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereofHOPE CITY·Filed 2013·Granted Nov 28, 2017·19 cites·8 claims
- 3094US6251399B1Immuno-reactive peptide CTL epitopes of human cytomegalovirusHOPE CITY·Filed 2000·Granted Jun 26, 2001·71 cites·9 claims
- 3193US12227745B2Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereofHOPE CITY·Filed 2023·Granted Feb 18, 2025·1 cites·20 claims
- 3293US11730797B2CS1 targeted chimeric antigen receptor-modified T cellsHOPE CITY·Filed 2020·Granted Aug 22, 2023·3 cites·9 claims
- 3393US11197919B2Chimeric antigen receptors targeting HER2HOPE CITY·Filed 2016·Granted Dec 14, 2021·11 cites·60 claims
- 3493US9580685B2Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selectionHOPE CITY·Filed 2014·Granted Feb 28, 2017·16 cites·23 claims
- 3593US9480526B2Microwave coaptive surgical sealing toolHOPE CITY·Filed 2015·Granted Nov 1, 2016·21 cites·12 claims
- 3693US9453227B2Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapyHOPE CITY·Filed 2013·Granted Sep 27, 2016·68 cites·9 claims
- 3793US8030290B2Cell-type specific aptamer-siRNA delivery system for HIV-1 TherapyHOPE CITY·Filed 2008·Granted Oct 4, 2011·13 cites·5 claims
- 3893US7914995B2Reaction mixture for pyrophosphorolysis activated polymerization (PAP)HOPE CITY·Filed 2009·Granted Mar 29, 2011·10 cites·5 claims
- 3993US7776330B2Humanized anti-CEA T84.66 antibody and uses thereofHOPE CITY·Filed 2007·Granted Aug 17, 2010·25 cites·9 claims
- 4092US12497440B2CS1 targeted chimeric antigen receptor-modified T cellsHOPE CITY·Filed 2023·Granted Dec 16, 2025·1 cites·14 claims
- 4192US12161714B2Use of endogenous viral vaccine in chimeric antigen receptor T cell therapyHOPE CITY·Filed 2023·Granted Dec 10, 2024·1 cites·6 claims
- 4292US11912995B2CTLA-4 aptamer conjugatesHOPE CITY·Filed 2021·Granted Feb 27, 2024·1 cites·17 claims
- 4392US11345656B2PCNA inhibitorsHOPE CITY·Filed 2020·Granted May 31, 2022·2 cites·24 claims
- 4492US11186840B2CTLA-4 aptamer conjugatesHOPE CITY·Filed 2020·Granted Nov 30, 2021·2 cites·14 claims
- 4592US11155783B2Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selectionHOPE CITY·Filed 2018·Granted Oct 26, 2021·3 cites·20 claims
- 4692US11141492B2Anticancer combinationsHOPE CITY·Filed 2015·Granted Oct 12, 2021·7 cites·14 claims
- 4792US10801026B2Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereofHOPE CITY·Filed 2016·Granted Oct 13, 2020·6 cites·15 claims
- 4892US10100314B2Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapyHOPE CITY·Filed 2016·Granted Oct 16, 2018·13 cites·19 claims
- 4992US9932310B2DNA2 inhibitors for cancer treatmentHOPE CITY·Filed 2017·Granted Apr 3, 2018·5 cites·13 claims
- 5092US9675689B2Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereofHOPE CITY·Filed 2013·Granted Jun 13, 2017·6 cites·23 claims
Showing the top 50 of 903 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →